Redhill Biopharma Ltd.

Xtl Biopharmaceuticals Ltd.

Vivoquest, Inc.

Redhill Bipharma Ltd.

Reza Fathi

Dror Ben-Asher

Guy Goldberg

Gilead Raday

Zhen Yang

Patrick Gosselin

Yixin Liu

Anthony Sandrasagra

Qiang Zhu

Yun Liao

Danielle Abramson

Kenneth Nawoschik

Hyun-Joon Cho

C Richard Wobbe

Youhong Hu

Ofra Barnett

Jie Wu

Patrick Laughlin Mclean

Bin Xu

Patrick Laughlin McLean

Harry Jefferson Leighton

Mark L Levitt

Mark Levitt

Kely Lee Sheldon

Ira Kalfus

Craig Miller

Joanne Speed

Guolin Li

Lisha Wang

Elliot Offman

Patricia Anderson

Wu Ruoqiu

Jie Cao

Angela Lam

The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.

Serine protease inhibitor for treating coronavirus infection

Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.

Therapy for inhibition of single-stranded RNA virus replication

The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.

Biomarkers of coronavirus pneumonia

Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection byor the prevention of recurrence of disorders associated with infection by

All-in-one fixed-dose combination for treatinginfection

A method of treating patients who are positive forinfection comprises determining that a first patient who is positive forinfection has a body mass index corresponding to normal weight or overweight; determining that a second patient who is positive forinfection has a body mass index corresponding to obese or extremely obese; and administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.

Method for eradicatinginfection in patients regardless of body mass index

Inhibitor of sphingosine kinase 2 for treating Ebola

Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.

Combination compositions for treatment of cancer

A fixed-dose combination drug product formulated for oral delivery comprises a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin. The fixed-dose combination drug product is sufficiently designed for use in treating pulmonaryComplex (MAC) disease in a subject in need thereof. A method for treating MAC disease in a human having MAC lung infection comprising orally administering, twice daily, about 475 mg of clarithromycin, about 40 mg of clofazimine and about 120 mg of rifabutin. A kit for treating pulmonary MAC disease in an individual having MAC lung infection comprises a supply of fixed-dose combination drug products, wherein each of the fixed-dose combination drug products comprise a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin; and instructions for use.

Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Sphingosine kinase 2 inhibitor for treating coronavirus infection

Rifabutin-based compositions and methods for treatinginfection

Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.

Compositions for treating ebola virus infection

Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.

Formulations and methods of manufacturing formulations for use in colonic evacuation

Growing community of inventors

Oradell, NJ, United States of America

Reza Fathi